175 related articles for article (PubMed ID: 38474094)
1. Phenotypic Analysis of Hematopoietic Stem and Progenitor Cell Populations in Acute Myeloid Leukemia Based on Spectral Flow Cytometry, a 20-Color Panel, and Unsupervised Learning Algorithms.
Matthes T
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474094
[TBL] [Abstract][Full Text] [Related]
2. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
3. Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach.
Wood BL
Curr Protoc Cytom; 2020 Jun; 93(1):e73. PubMed ID: 32311834
[TBL] [Abstract][Full Text] [Related]
4. Development of a 27-color panel for the detection of measurable residual disease in patients diagnosed with acute myeloid leukemia.
Soh KT; Conway A; Liu X; Wallace PK
Cytometry A; 2022 Nov; 101(11):970-983. PubMed ID: 35716345
[TBL] [Abstract][Full Text] [Related]
5. The impact of Down syndrome-specific non-malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease.
Hsu FC; Hudson C; Wilson ER; Pardo LM; Singleton TP; Xu D; Zehentner BK; Hitzler J; Berman J; Wells DA; Loken MR; Brodersen LE
Cytometry B Clin Cytom; 2023 Jul; 104(4):311-318. PubMed ID: 37015883
[TBL] [Abstract][Full Text] [Related]
6. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
[TBL] [Abstract][Full Text] [Related]
7. Identification of functionally primitive and immunophenotypically distinct subpopulations in secondary acute myeloid leukemia by mass cytometry.
Bandyopadhyay S; Fowles JS; Yu L; Fisher DAC; Oh ST
Cytometry B Clin Cytom; 2019 Jan; 96(1):46-56. PubMed ID: 30426661
[TBL] [Abstract][Full Text] [Related]
8. Characterization of myelodysplastic syndromes hematopoietic stem and progenitor cells using mass cytometry.
Bachas C; Duetz C; van Spronsen MF; Verhoeff J; Garcia Vallejo JJ; Jansen JH; Cloos J; Westers TM; van de Loosdrecht AA
Cytometry B Clin Cytom; 2023 Mar; 104(2):128-140. PubMed ID: 35289472
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo.
Knorr KL; Finn LE; Smith BD; Hess AD; Foran JM; Karp JE; Kaufmann SH
Stem Cells Transl Med; 2017 Mar; 6(3):840-850. PubMed ID: 28297583
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
[TBL] [Abstract][Full Text] [Related]
11. A 19-color single-tube full spectrum flow cytometry assay for the detection of measurable residual disease in acute myeloid leukemia.
Fokken H; Waclawski J; Kattre N; Kloos A; Müller S; Ettinger M; Kacprowski T; Heuser M; Maetzig T; Schwarzer A
Cytometry A; 2024 Mar; 105(3):181-195. PubMed ID: 37984809
[TBL] [Abstract][Full Text] [Related]
12. Impact of the gating strategy for Ki-67 and Bcl-2 on the determination of proliferation and anti-apoptosis data by flow cytometry in non-malignant bone marrow aspirates and aspirates from patients with myeloid malignancies.
Mestrum SGC; Vanblarcum RBY; de Wit NCJ; Drent RJM; Boonen BT; van Hemert WLW; Hopman AHN; Ramaekers FCS; Leers MPG
Data Brief; 2023 Aug; 49():109284. PubMed ID: 37409174
[TBL] [Abstract][Full Text] [Related]
13. CD34+ cell subpopulations detected by 8-color flow cytometry in bone marrow and in peripheral blood stem cell collections: application for MRD detection in leukemia patients.
Björklund E; Gruber A; Mazur J; Mårtensson A; Hansson M; Porwit A
Int J Hematol; 2009 Oct; 90(3):292-302. PubMed ID: 19728029
[TBL] [Abstract][Full Text] [Related]
14. Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.
Getta BM; Devlin SM; Levine RL; Arcila ME; Mohanty AS; Zehir A; Tallman MS; Giralt SA; Roshal M
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1064-1071. PubMed ID: 28315400
[TBL] [Abstract][Full Text] [Related]
15. Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.
Zhou Y; Othus M; Araki D; Wood BL; Radich JP; Halpern AB; Mielcarek M; Estey EH; Appelbaum FR; Walter RB
Leukemia; 2016 Jul; 30(7):1456-64. PubMed ID: 27012865
[TBL] [Abstract][Full Text] [Related]
16. The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia.
Czyz A; Nagler A
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661875
[TBL] [Abstract][Full Text] [Related]
17. Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts.
Chea M; Rigolot L; Canali A; Vergez F
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396825
[TBL] [Abstract][Full Text] [Related]
18. An R-Derived FlowSOM Process to Analyze Unsupervised Clustering of Normal and Malignant Human Bone Marrow Classical Flow Cytometry Data.
Lacombe F; Lechevalier N; Vial JP; Béné MC
Cytometry A; 2019 Nov; 95(11):1191-1197. PubMed ID: 31577391
[TBL] [Abstract][Full Text] [Related]
19. Identification of critical hemodilution by artificial intelligence in bone marrow assessed for minimal residual disease analysis in acute myeloid leukemia: The Cinderella method.
Hoffmann J; Thrun MC; Röhnert MA; von Bonin M; Oelschlägel U; Neubauer A; Ultsch A; Brendel C
Cytometry A; 2023 Apr; 103(4):304-312. PubMed ID: 36030398
[TBL] [Abstract][Full Text] [Related]
20. Characterization of CD34
Nollmann C; Moskorz W; Wimmenauer C; Jäger PS; Cadeddu RP; Timm J; Heinzel T; Haas R
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
